142 related articles for article (PubMed ID: 1495798)
1. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.
Glaser BM; Michels RG; Kuppermann BD; Sjaarda RN; Pena RA
Ophthalmology; 1992 Jul; 99(7):1162-72; discussion 1173. PubMed ID: 1495798
[TBL] [Abstract][Full Text] [Related]
2. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes.
Lansing MB; Glaser BM; Liss H; Hanham A; Thompson JT; Sjaarda RN; Gordon AJ
Ophthalmology; 1993 Jun; 100(6):868-71; discussion 871-2. PubMed ID: 8510899
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study.
Smiddy WE; Glaser BM; Thompson JT; Sjaarda RN; Flynn HW; Hanham A; Murphy RP
Retina; 1993; 13(4):296-301. PubMed ID: 8115729
[TBL] [Abstract][Full Text] [Related]
4. Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2.
Thompson JT; Hiner CJ; Glaser BM; Gordon AJ; Murphy RP; Sjaarda RN
Am J Ophthalmol; 1994 Mar; 117(3):291-301. PubMed ID: 8129001
[TBL] [Abstract][Full Text] [Related]
5. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP
Am J Ophthalmol; 1995 Jan; 119(1):48-54. PubMed ID: 7825689
[TBL] [Abstract][Full Text] [Related]
6. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.
Thompson JT; Smiddy WE; Williams GA; Sjaarda RN; Flynn HW; Margherio RR; Abrams GW
Ophthalmology; 1998 Apr; 105(4):700-6. PubMed ID: 9544645
[TBL] [Abstract][Full Text] [Related]
7. The results of vitreous surgery for chronic macular holes.
Thompson JT; Sjaarda RN; Lansing MB
Retina; 1997; 17(6):493-501. PubMed ID: 9428011
[TBL] [Abstract][Full Text] [Related]
8. Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes.
Rubin JS; Glaser BM; Thompson JT; Sjaarda RN; Pappas SS; Murphy RP
Ophthalmology; 1995 Dec; 102(12):1840-5. PubMed ID: 9098285
[TBL] [Abstract][Full Text] [Related]
9. Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study.
Ie D; Glaser BM; Thompson JT; Sjaarda RN; Gordon LW
Ophthalmology; 1993 Dec; 100(12):1787-93. PubMed ID: 8259275
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
Blumenkranz MS; Ohana E; Shaikh S; Chang S; Coll G; Morse LS; De Bustros S
Ophthalmic Surg Lasers; 2001; 32(3):198-207. PubMed ID: 11371086
[TBL] [Abstract][Full Text] [Related]
11. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2.
Thompson JT; Glaser BM; Sjaarda RN; Murphy RP; Hanham A
Ophthalmology; 1994 Jul; 101(7):1195-200. PubMed ID: 8035983
[TBL] [Abstract][Full Text] [Related]
12. Human autologous serum for the treatment of full-thickness macular holes. A preliminary study.
Liggett PE; Skolik DS; Horio B; Saito Y; Alfaro V; Mieler W
Ophthalmology; 1995 Jul; 102(7):1071-6. PubMed ID: 9121755
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
Minihan M; Goggin M; Cleary PE
Br J Ophthalmol; 1997 Dec; 81(12):1073-9. PubMed ID: 9497468
[TBL] [Abstract][Full Text] [Related]
14. Full-thickness macular holes treated with vitrectomy and tissue glue.
Tilanus MA; Deutman AF
Int Ophthalmol; 1994-1995; 18(6):355-8. PubMed ID: 7642336
[TBL] [Abstract][Full Text] [Related]
15. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The Vitrectomy for Treatment of Macular Hole Study Group.
Freeman WR; Azen SP; Kim JW; el-Haig W; Mishell DR; Bailey I
Arch Ophthalmol; 1997 Jan; 115(1):11-21. PubMed ID: 9006420
[TBL] [Abstract][Full Text] [Related]
16. Full-thickness macular hole formation in eyes with a pre-existing complete posterior vitreous detachment.
Gordon LW; Glaser BM; Ie D; Thompson JT; Sjaarda RN
Ophthalmology; 1995 Nov; 102(11):1702-5. PubMed ID: 9098265
[TBL] [Abstract][Full Text] [Related]
17. Anatomical and visual outcomes after episcleral macular buckling compared with those after pars plana vitrectomy for retinal detachment caused by macular hole in highly myopic eyes.
Ando F; Ohba N; Touura K; Hirose H
Retina; 2007 Jan; 27(1):37-44. PubMed ID: 17218913
[TBL] [Abstract][Full Text] [Related]
18. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study.
Korobelnik JF; Hannouche D; Belayachi N; Branger M; Guez JE; Hoang-Xuan T
Ophthalmology; 1996 Apr; 103(4):590-4. PubMed ID: 8618757
[TBL] [Abstract][Full Text] [Related]
19. Internal limiting membrane removal in the management of full-thickness macular holes.
Mester V; Kuhn F
Am J Ophthalmol; 2000 Jun; 129(6):769-77. PubMed ID: 10926987
[TBL] [Abstract][Full Text] [Related]
20. Management of macular holes that develop after retinal detachment repair.
Moshfeghi AA; Salam GA; Deramo VA; Shakin EP; Ferrone PJ; Shakin JL; Fastenberg DM
Am J Ophthalmol; 2003 Nov; 136(5):895-9. PubMed ID: 14597042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
